YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Acrivon Therapeutics press release [https://seekingalpha.com/pr/20617353-acrivon-reports-second-quarter-2026-financial-results-and-highlights-upcoming-2026-clinical] (ACRV [https://seekingalpha.com/symbol/ACRV]): Q2 GAAP EPS of -$0.43 be…
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index Early clinical responses, includin…
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 The ACR-2316 Phase 1…
(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis. - ScinoPharm secures FDA nod for Glatiramer Acet…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Jet.AI Inc. 97,548,193 0.8655 0.6914 0.7747 +0.2147 Oriental Culture Holdi…
(RTTNews) - Several biotechnology and healthcare companies posted notable gains in after-hours trading on Wednesday, driven by clinical updates, financial results, and upcoming industry presentations. ALX Oncology Holdings Inc. (ALXO) surg…
With the recent surge in U.S. stock markets following the Federal Reserve's interest rate cuts, investors are keenly observing how these changes might impact various sectors. While major indices like the S&P 500 and Dow Jones have shown si…
With strong three-month performance and significant upside potential, Acrivon Therapeutics, Inc. (NASDAQ:ACRV) secures a spot on our list of the 12 hot penny stocks to invest in right now.H.C. Wainwright Initiates Coverage on Acrivon Thera…
Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Ex…
Major stock indexes in the United States have recently experienced a pullback, with technology shares leading the decline. Despite these broader market challenges, certain investment opportunities remain attractive, particularly within the…
AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical data, demonstrating its differenti…
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its propri…
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session. [unusualvolume] TODAY'S UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PT [https://www.chartmill.co…
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT GTBP [https://www.chartmill.com/stock/quote/GTBP/profile] 29.79…
Investing.com - JMP Securities has reiterated its Market Outperform rating and $13.00 price target on Acrivon Therapeutics Inc (NASDAQ:ACRV), according to a research note released Friday. The stock, which has seen a 12% gain over the past…
Key Points GAAP net loss per share for Q2 2025 was $(0.55), slightly beating the estimated GAAP loss of $(0.57). No product or collaboration revenue was reported as the company remains in clinical development. Increased research and develo…
* Acrivon Therapeutics press release [https://seekingalpha.com/pr/20200234-acrivon-therapeutics-reports-second-quarter-2025-financial-results-and-business-highlights] (NASDAQ:ACRV [https://seekingalpha.com/symbol/ACRV]): Q2 GAAP EPS of -$0…
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predict…
JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research…
Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR)…
Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-23…
Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the pa…
Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive ACR-368 endometrial cancer data in O…
Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 st…
The ACR-368-tailored OncoSignature assay is being used in Acrivon’s ongoing registrational-intent Phase 2 trial to predict patients most likely to respond to the CHK1/2 inhibitor ACR-368 in three tumor types Drug-tailored, proprietary Onco…
WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…
WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…
WATERTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…
Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction of patients, as wel…
WATERTOWN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pat…
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pat…
Acrivon's Predictive Precision Proteomics (AP3) platform is a proprietary, broadly applicable, next-generation precision oncology platform at the forefront of the next wave of biology-driven drug discovery, in addition to its previously de…
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…
WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…
WATERTOWN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…
WATERTOWN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to pati…